These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 31010313)

  • 1. Sustained Glycemic Control With Ivacaftor in Cystic Fibrosis-Related Diabetes.
    Christian F; Thierman A; Shirley E; Allen K; Cross C; Jones K
    J Investig Med High Impact Case Rep; 2019; 7():2324709619842898. PubMed ID: 31010313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study.
    Bellin MD; Laguna T; Leschyshyn J; Regelmann W; Dunitz J; Billings J; Moran A
    Pediatr Diabetes; 2013 Sep; 14(6):417-21. PubMed ID: 23952705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of triple transmembrane regulator therapy on glucose metabolism in cystic fibrosis related diabetes during clinical practice.
    Aguilera García I; García Moreno RM; López Plaza B; Barquiel Alcalá B; Vázquez Pérez P; Barreda Bonis AC; Zamarrón de Lucas E; Palma Milla S; Prados Sánchez MC; González Pérez de Villar N
    Diabetes Res Clin Pract; 2024 Oct; 216():111839. PubMed ID: 39187175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The course of glucose intolerance in children with cystic fibrosis: a retrospective study - preliminary report.
    Piechowiak K; Trippenbach-Dulska H; Walicka-Serzysko K
    Dev Period Med; 2015; 19(1):80-91. PubMed ID: 26003073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of CFTR modulator therapy on cystic fibrosis-related diabetes.
    Gaines H; Jones KR; Lim J; Medhi NF; Chen S; Scofield RH
    J Diabetes Complications; 2021 Jun; 35(6):107845. PubMed ID: 33558149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients.
    Moheet A; Beisang D; Zhang L; Sagel SD; VanDalfsen JM; Heltshe SL; Frederick C; Mann M; Antos N; Billings J; Rowe SM; Moran A;
    J Cyst Fibros; 2021 Mar; 20(2):333-338. PubMed ID: 32917547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Lumacaftor/Ivacaftor on glucose metabolism and insulin secretion in Phe508del homozygous cystic fibrosis patients.
    Thomassen JC; Mueller MI; Alejandre Alcazar MA; Rietschel E; van Koningsbruggen-Rietschel S
    J Cyst Fibros; 2018 Mar; 17(2):271-275. PubMed ID: 29249670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term therapy with CFTR modulators consistently improves glucose metabolism in adolescents and adults with cystic fibrosis.
    Cohen A; Mass A; Reiter J; Zangen DH; Cohen-Cymberknoh M
    Respir Med; 2024 Jul; 228():107664. PubMed ID: 38759874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CFTR potentiator therapy ameliorates impaired insulin secretion in CF patients with a gating mutation.
    Tsabari R; Elyashar HI; Cymberknowh MC; Breuer O; Armoni S; Livnat G; Kerem E; Zangen DH
    J Cyst Fibros; 2016 May; 15(3):e25-7. PubMed ID: 26547591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological management of cystic fibrosis related diabetes.
    Moheet A; Moran A
    Expert Rev Clin Pharmacol; 2018 Feb; 11(2):185-191. PubMed ID: 29268054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement in bronchiectasis on CT imaging in a pediatric patient with cystic fibrosis on ivacaftor therapy.
    Hayes D; Long FR; McCoy KS; Sheikh SI
    Respiration; 2014; 88(4):345. PubMed ID: 25171465
    [No Abstract]   [Full Text] [Related]  

  • 12. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.
    Konstan MW; McKone EF; Moss RB; Marigowda G; Tian S; Waltz D; Huang X; Lubarsky B; Rubin J; Millar SJ; Pasta DJ; Mayer-Hamblett N; Goss CH; Morgan W; Sawicki GS
    Lancet Respir Med; 2017 Feb; 5(2):107-118. PubMed ID: 28011037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetes in cystic fibrosis.
    Bridges N
    Paediatr Respir Rev; 2013 May; 14 Suppl 1():16-8. PubMed ID: 23522600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor-ivacaftor.
    Li A; Vigers T; Pyle L; Zemanick E; Nadeau K; Sagel SD; Chan CL
    J Cyst Fibros; 2019 Jan; 18(1):144-149. PubMed ID: 30104123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
    Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC;
    Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Islet Hormone and Incretin Secretion in Cystic Fibrosis after Four Months of Ivacaftor Therapy.
    Kelly A; De Leon DD; Sheikh S; Camburn D; Kubrak C; Peleckis AJ; Stefanovski D; Hadjiliadis D; Rickels MR; Rubenstein RC
    Am J Respir Crit Care Med; 2019 Feb; 199(3):342-351. PubMed ID: 30130412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.
    Wainwright CE; Elborn JS; Ramsey BW; Marigowda G; Huang X; Cipolli M; Colombo C; Davies JC; De Boeck K; Flume PA; Konstan MW; McColley SA; McCoy K; McKone EF; Munck A; Ratjen F; Rowe SM; Waltz D; Boyle MP; ;
    N Engl J Med; 2015 Jul; 373(3):220-31. PubMed ID: 25981758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ataluren/ivacaftor combination therapy: Two N-of-1 trials in cystic fibrosis patients with nonsense mutations.
    Peabody Lever JE; Mutyam V; Hathorne HY; Peng N; Sharma J; Edwards LJ; Rowe SM
    Pediatr Pulmonol; 2020 Jul; 55(7):1838-1842. PubMed ID: 32281737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
    Heijerman HGM; McKone EF; Downey DG; Van Braeckel E; Rowe SM; Tullis E; Mall MA; Welter JJ; Ramsey BW; McKee CM; Marigowda G; Moskowitz SM; Waltz D; Sosnay PR; Simard C; Ahluwalia N; Xuan F; Zhang Y; Taylor-Cousar JL; McCoy KS;
    Lancet; 2019 Nov; 394(10212):1940-1948. PubMed ID: 31679946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR.
    Donaldson SH; Pilewski JM; Griese M; Cooke J; Viswanathan L; Tullis E; Davies JC; Lekstrom-Himes JA; Wang LT;
    Am J Respir Crit Care Med; 2018 Jan; 197(2):214-224. PubMed ID: 28930490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.